Table 1.
Patient characteristics.
| Characteristics | All patients |
|---|---|
| (n = 44) | |
| Age | |
| Median (range) | 69 (39-79) |
| Sex | |
| Male | 30 (68.2%) |
| Female | 14 (31.8%) |
| ECOG-performance status | |
| 0 | 17 (38.6%) |
| 1 | 24 (54.6%) |
| 2 | 3 (6.8%) |
| Stage | |
| III/IV | 41 (93.2%) |
| Recurrence | 3 (6.8%) |
| Oncogenic driver | |
| EGFR mutation positivity | 6 (13.6%) |
| ALK rearranged positivity | 0 (0.0%) |
| Smoking status | |
| Current/former | 34 (77.3%) |
| Never | 10 (22.7%) |
| Histology | |
| Adeno | 31 (70.5%) |
| Squamous | 8 (18.2%) |
| Others | 5 (11.4%) |
| PD-L1 status | |
| <1% | 16 (36.4%) |
| 1-49% | 19 (43.2%) |
| ≥50% | 9 (20.5%) |
| Metastasis sites | |
| Brain | 13 (19.6%) |
| Liver | 3 (6.8%) |
| Bone | 15 (34.1%) |
| Interval from combined chemoimmunotherapy to RAM + DOC, days | |
| Median (range) | 32.5 (14-505) |
| Previous combined chemoimmunotherapy regimen | |
| Platinum + pemetrexed + pembrolizumab | 22 (50.0%) |
| Platinum + paclitaxel/nab-paclitaxel + pembrolizumab | 8 (18.2%) |
| Platinum + paclitaxel/pemetrexed + bevacizumab + atezolizumab | 9 (20.5%) |
| Platinum + pemetrexed + atezolizumab | 2 (4.5%) |
| Platinum + paclitaxel/nab-paclitaxel + atezolizumab | 1 (2.3%) |
| Platinum + pemetrexed + ipilimumab + nivolumab | 2 (4.5%) |
| Reasons for discontinuation of combined chemoimmunotherapy | |
| Due to progression disease | 38 (86.4%) |
| Due to adverse event | 6 (13.6%) |